Researchers from Truveta have found that adoption of adalimumab biosimilars increased substantially following formulary changes in the United States, though more than one in seven patients who ...

Stanford scientists just reported that they've been using AI technology to design the tastiest hamburger. But they did not ...

Seeking to replace blockbuster drugs that will soon lose patent protection, drug-maker AbbVie purchased a biotech firm for ...

Detailed price information for Apogee Therapeutics Inc (APGE-Q) from The Globe and Mail including charting and trades.

AbbVie said on Monday it ⁠would ⁠buy Apogee Therapeutics for $10.9 billion, the ⁠company's largest buyout in more than five ...

AbbVie's post-Humira growth story has been a triumph, but the single drug driving that narrative is showing the first hint of ...

Doctors have few options for patients who develop a life-threatening lung condition called acute respiratory distress syndrome, or ARDS. A frequent cause of death during the COVID-19 pandemic, ARDS ...

I hit the buy button on AbbVie (NYSE:ABBV) again last week, and I will hit it again the next time June’s macro noise hands me ...

AbbVie said on Monday it would buy biotech Apogee ⁠Therapeutics for $10.9 billion, its largest buyout in more than five years ...

Doctors have few options for patients who develop a life-threatening lung condition called acute respiratory distress ...

Looking for the latest dividend stock opportunities in July 2026? Click to which dividend stocks may be worth snagging now to up your passive income.

Big pharma’s patent cliff may be overstated: layered IP, incremental innovation, and smart licensing extend exclusivity and ...